This site is intended for Healthcare Professionals only.

Zentiva launches Buspirone 15mg and 30mg strength tablets

Date:

Share post:

Zentiva, one of the leading developers and suppliers of prescription medicines and consumer brands has launched 15 mg and 30 mg Buspirone tablets.

This medication is indicated for the treatment of short-term management of anxiety disorders and the relief of symptoms of anxiety with or without accompanying symptoms of depression.

Luke Hart, General Manager commented, “Zentiva is excited to announce this new addition to our Value Added Medicines portfolio, continuing to meet the unfulfilled needs of patients.”

He continues, “the launch of our 15mg and 30mg Buspirone Tablets will enable more flexible and accurate dosing – allowing for simple and convenient dosing regimens for patients with anxiety disorders.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Opioid overdose: Pharmacy professionals to be able to supply naloxone without a prescription

DHSC also publishes a new 10-year strategic plan to expand and improve the drug and alcohol workforce The...

New NHS patient choice scheme offers 5 options, but nursing shortages persist

Royal College of Nursing CE urges caution amidst new NHS patient choice pilot scheme rollout "Patients deserve choice, but...

Prof Ryan Donnelly awarded prestigious RPS Harrison Memorial Medal 2024

RPS HMM winner Professor Donnelly's work has secured £30M+ funding through his pioneering work in developing advanced polymeric...

Pharmacies forced to subsidise NHS medicines: NPA hands £108m invoice to DHSC

The NPA calls for a new deal that reverses “historical funding cuts and gives the sector the respect...